BeOne Medicines AG (ONC)
| Market Cap | 42.11B +21.6% |
| Revenue (ttm) | 6.13B +34.3% |
| Net Income | 655.71M |
| EPS | 5.59 |
| Shares Out | 113.70M |
| PE Ratio | 66.28 |
| Forward PE | 45.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292,815 |
| Open | 369.77 |
| Previous Close | 371.56 |
| Day's Range | 368.49 - 376.45 |
| 52-Week Range | 253.95 - 388.66 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 437.57 (+18.16%) |
| Earnings Date | Nov 5, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $437.57, which is an increase of 18.16% from the latest price.
News
BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026
BeOne Medicines (ONC) announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology, ESMO, Congre...
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve...
BeOne Medicines reports ‘sustained survival benefit’ with TEVIMBRA-ZIIHERA combo
BeOne Medicines (ONC) announced new survival results from the planned second interim analysis and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA ...
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned seco...
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Th...
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progress...
BeOne Medicines price target raised to $425 from $405 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $425 from $405 and keeps an Overweight rating on the shares. The firm, which sees…
BeOne Medicines price target raised to $459 from $450 at RBC Capital
RBC Capital raised the firm’s price target on BeOne Medicines (ONC) to $459 from $450 and keeps an Outperform rating on the shares as part of a broader research note…
BeOne Medicines price target raised to $420 from $418 at Truist
Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $420 from $418 and keeps a Buy rating on the shares as part of a broader…
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
BeOne Medicines price target raised to $445 from $425 at JPMorgan
JPMorgan analyst Jessica Fye raised the firm’s price target on BeOne Medicines (ONC) to $445 from $425 and keeps an Overweight rating on the shares ahead of the Q3 report.
BeOne Medicines AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into a global oncology leader with a robust pipeline, highlighted by pivotal solid tumor and hematology programs, strong commercial growth, and strategic partnerships. Financial guidance was raised on the back of BRUKINSA's performance, while ongoing innovation and global expansion remain priorities.
BeOne Medicines price target raised to $415 from $407 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $415 from $407 and keeps an Overweight rating on the shares after the FDA approved Ziihera and Tevimbra for…
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley ...
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
BeOne Medicines to expand access to cancer medicines under pact with U.S.
BeOne Medicines (ONC) announced a voluntary agreement with the U.S. Government to “expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprin...
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Gover...
BeOne Medicines announces new Phase 3 survival data on Ziihera
BeOne Medicines (ONC) announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera, in combination with chemotherapy, with and without Tev...
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second i...
BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA
BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of ...
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines renews partnerships to expand access to Brukinsa in leukemia
BeOne Medicines (ONC), together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a global health nonprofit organization, announced the renewal of their partne...
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundatio...
BeOne Medicines price target raised to $370 from $340 at Wolfe Research
Wolfe Research analyst Kalpit Patel raised the firm’s price target on BeOne Medicines (ONC) to $370 from $340 and keeps an Outperform rating on the shares. BeOne’s $300M guidance increase…
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncolog...